SGLT2 inhibitors (SGLT2is) are now a key pillar in the treatment with heart failure (HF). Adding an SGLT2i to standard HF therapy can cut the risk of cardiovascular death or HF hospitalization by one-third. A new CardioSmart infographic helps patients understand the benefits of this new class of drugs, possible side effects and questions to discuss with their health care team, all part of facilitating crucial shared decision-making conversations. In addition, the ACC recently released a clinician infographic and pocket guide on SGLT2is. Both tools were polybagged with the latest issue of Cardiology magazine to support clinicians in implementing this guideline-directed treatment through optimal patient selection, drug initiation and sequencing. Download the tools here.